Lars‐Olof Mügge

Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia

Sebastian Scholl, Claudia med. Theuer, Veit Scheble et al. · European Journal Of Haematology · 2007 · 69 citations

Life Sciences, Hematology, Molecular Genetics +14

The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey

Annamaria Brioli, Maximilian Klaus, Herbert G. Sayer et al. · Annals of Hematology · 2019 · 54 citations

Medicine, Hematology, Oncology +14

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Meletios Α. Dimopoulos, Paul G. Richardson, Nizar J. Bahlis et al. · The Lancet Haematology · 2022 · 47 citations

Medicine, Oncology, Pharmacotherapy +12

Velcade, Intravenous Cyclophosphamide and Dexamethasone (VCD) Induction for Previously Untreated Multiple Myeloma (German DSMM XIa Trial).

Hermann Einsele, Peter Liebisch, Christian Langer et al. · Blood · 2009 · 43 citations

Medicine, Hematology, Oncology +11

Rapid screening and sensitive detection of NPM1 (nucleophosmin) exon 12 mutations in acute myeloid leukaemia

Sebastian Scholl, Lars‐Olof Mügge, Olfert Landt et al. · Leukemia Research · 2007 · 33 citations

Medicine, Genetics, Molecular Genetics +12